Omnicell Inc
Omnicell Inc (OMCL) designs and sells medication management and pharmacy automation solutions for hospitals, retail pharmacies and other healthcare providers. The business combines hardware (dispensing systems), software (workflow and analytics) and services (installation, maintenance, consumables), creating a mix of product sales and recurring revenue. With a market capitalisation of around $1.42 billion, Omnicell aims to help customers cut errors and improve efficiency, but growth depends on hospital capital cycles, technology adoption and competition. Investors should weigh the potential for steady service revenues and software uptake against execution and regulatory risks, competitive pressure and occasional lumpy sales. This summary is general information only and not personalised advice — prospective investors should review the latest regulatory filings, earnings reports and professional guidance before deciding whether OMCL fits their portfolio and risk tolerance.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Omnicell's stock, anticipating it will rise towards the target price.
Financial Health
Omnicell Inc is performing well with solid revenue, cash flow, and profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring OMCL
Pharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: October 12, 2025
Explore BasketPharma Onshoring Boom: Investment Risk Considerations
AstraZeneca is building a major new manufacturing plant in the U.S., responding to policy pressures for domestic production. This signals a broader trend of onshoring pharmaceutical manufacturing, creating opportunities for companies that build and equip these advanced facilities.
Published: October 10, 2025
Explore BasketInjectable Drug Innovation Opportunities 2025
The FDA's approval of an at-home injectable version of Eisai and Biogen's Alzheimer's drug, Leqembi, simplifies treatment for patients and caregivers. This development highlights a growing trend toward patient-centric care, creating investment opportunities in companies that specialize in innovative drug delivery systems and at-home therapeutic technologies.
Published: August 31, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Automation and Efficiency
Automation of pharmacy workflows can reduce errors and operating costs, and long-term contracts may support recurring revenue, though adoption cycles can be lengthy.
Recurring Revenue Mix
Software licences, services and consumables provide steadier income than one-off equipment sales, yet competition and pricing pressure can affect margins.
Regulatory & Execution Risks
Regulation, product integration and successful execution on new offerings are important risks; outcomes can vary and investors should assess recent operational trends.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
